Table 3.
Pharmacokinetic parameters after intravenous or oral administration of docetaxel formulations to rats
| Intravenous taxotere® | Oral | |||
|---|---|---|---|---|
|
| ||||
| DTX-LNs | DTX solution | DTX solution with CsA | ||
| Dose (mg/kg) | 20 | 20 | 20 | 20 |
| Tmax (h) | 0.033 | 1 | 0.5 | 0.5 |
| Cmax (ng/mL) | – | 116.19 ± 28.58** | 28.99 ± 8.84 | 37.20 ± 15.16# |
| AUC (h · ng/mL) | 5608.66 ± 282.46 | 490.74 ± 37.28** | 134.83 ± 21.46 | 222.63 ± 29.01## |
| CLt (L/h/kg) | 3.57 ± 0.18 | 40.95 ± 3.16** | 151.55 ± 25.45 | 91.24 ± 13.55## |
| MRT (h) | 1.06 ± 0.07 | 5.60 ± 0.34 | 4.78 ± 1.18 | 5.44 ± 0.56 |
| F (%) | – | 8.75 | 2.40 | 3.97 |
Notes: The values represent mean ± standard deviation (n = 5);
**
P < 0.01 compared with docetaxel solution;
#
P < 0.05 compared with docetaxel-loaded lecithin nanoparticles;
##
P < 0.01 compared with docetaxel-loaded lecithin nanoparticles.
Abbreviations: AUC, area under the curve; CLt, total clearance; Cmax, maximum plasma concentration; CsA, cyclosporine A; DTX, docetaxel; DTX-LNs, docetaxel-loaded lecithin nanoparticles; F, bioavailability; h, hours; MRT, mean retention time; Tmax, time to maximum plasma concentration.